The confirmed target interactions suggest an attenuation of pulmonary vascular remodeling, modulation of HCV viral response, and hypomagnesemia, thus it does not endorse the hypothesis of elevated thrombosis or viral infections/reactivation risk explained by one (or more) drug-target interactions. Consequently, the current safety concerns may be due to underlying patient-specific factors (confounders) or to targets not detected by our computational pipeline, but as not all of the predicted targets related to thrombosis or viral infection/reactivation were experimentally validated further research is warranted. Finally, baricitinib and tofacitinib may be potential candidates for repurposing, as they were identified as drugs with promiscuous binding activity.